Cetuximab

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37]

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37]

In the first trial, 676 chemotherapy-naïve patients with stage IIIB (pleural effusion) or stage IV NSCLC, without restrictions by histology or EGFR expression, received cetuximab with taxane (paclitaxel or docetaxel with carboplatin) or combination chemotherapy.[36]

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37] › In the first trial, 676 chemotherapy-naïve patients with stage IIIB (pleural effusion) or stage IV NSCLC, without restrictions by histology or EGFR expression, received cetuximab with taxane (paclitaxel or docetaxel with carboplatin) or combination chemotherapy.[36]

The addition of cetuximab did not result in a statistically significant improvement in PFS, the primary study end point, or OS.

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37] › In the first trial, 676 chemotherapy-naïve patients with stage IIIB (pleural effusion) or stage IV NSCLC, without restrictions by histology or EGFR expression, received cetuximab with taxane (paclitaxel or docetaxel with carboplatin) or combination chemotherapy.[36]

Median PFS was 4.40 months for patients in the cetuximab-chemotherapy arm versus 4.24 months for patients in the taxane-carboplatin arm (HR, 0.902; 95% CI, 0.761–1.069; P = .236).

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37] › In the first trial, 676 chemotherapy-naïve patients with stage IIIB (pleural effusion) or stage IV NSCLC, without restrictions by histology or EGFR expression, received cetuximab with taxane (paclitaxel or docetaxel with carboplatin) or combination chemotherapy.[36]

Median OS was 9.69 months for patients in the cetuximab-chemotherapy arm versus 8.38 months for patients in the chemotherapy-alone arm (HR, 0.890; 95% CI, 0.754–1.051; P = .169).

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37] › In the first trial, 676 chemotherapy-naïve patients with stage IIIB (pleural effusion) or stage IV NSCLC, without restrictions by histology or EGFR expression, received cetuximab with taxane (paclitaxel or docetaxel with carboplatin) or combination chemotherapy.[36]

In treatment-specific analyses, PFS, OS, and response were not significantly associated with EGFR expression, EGFR variants, EGFR copy number, or KRAS variants.[38]

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37]

The second trial was composed of 1,125 chemotherapy-naïve patients with advanced EGFR-expressing stage IIIB/IV NSCLC treated with cisplatin-vinorelbine chemotherapy plus cetuximab or chemotherapy alone.[37]

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37] › The second trial was composed of 1,125 chemotherapy-naïve patients with advanced EGFR-expressing stage IIIB/IV NSCLC treated with cisplatin-vinorelbine chemotherapy plus cetuximab or chemotherapy alone.[37]

The primary study end point, OS, was longer for patients treated with cetuximab and chemotherapy (median 11.3 months vs. 10.1 months; HRdeath, 0.871; 95% CI, 0.762–0.996; P = .044).

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37] › The second trial was composed of 1,125 chemotherapy-naïve patients with advanced EGFR-expressing stage IIIB/IV NSCLC treated with cisplatin-vinorelbine chemotherapy plus cetuximab or chemotherapy alone.[37]

A survival benefit was seen in all histological subgroups; however, survival benefit was not seen in non-White or Asian patients. Only the interaction between the treatment and the ethnic origin was significant (P = .011).

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37] › The second trial was composed of 1,125 chemotherapy-naïve patients with advanced EGFR-expressing stage IIIB/IV NSCLC treated with cisplatin-vinorelbine chemotherapy plus cetuximab or chemotherapy alone.[37]

The main cetuximab-related adverse event was acne-like rash (grade 3, 10%).

Two trials have evaluated the addition of cetuximab to first-line combination chemotherapy.[36,37]

It is not clear whether the differences in outcome in these two studies are the result of differences in the study populations, tumor characterization for EGFR expression, or chemotherapy regimens.